TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11134877

Group type: EXPERIMENTAL
Intervention: CeeOn 912 using Nichamin implantation forceps
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: AcrySof MA30BA using Buratto implantation forceps
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: SI‐55NB using Fine Universal II Folder
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: SI‐55NB using AMO Unfolder
Number of subjects: 40

Group type: COMPARATOR
Intervention: SI‐55NB with Unfolder vs Fine folder
Number of subjects: 40
Study: 9113009

Group type: EXPERIMENTAL
Intervention: Low-protein diet (0.8-1.1 g/kg daily adjusted for age)
Number of subjects: 191

Group type: COMPARATOR
Intervention: Control group (standard protein intake)
Number of subjects: 191
Study: 7690093

Group type: EXPERIMENTAL
Intervention: Atenolol 300 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Diltiazem 300 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 3527810

Group type: EXPERIMENTAL
Intervention: Diuretics
Number of subjects: 1114

Group type: EXPERIMENTAL
Intervention: Methylprednisolone sodium succinate (MPSS)
Number of subjects: 1114

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1114

Group type: EXPERIMENTAL
Intervention: Treatment within 6 hours of chest pain onset
Number of subjects: 1114

Group type: EXPERIMENTAL
Intervention: Treatment 6 to 12 hours after chest pain onset
Number of subjects: 1114
Study: 30062657

Group type: EXPERIMENTAL
Intervention: Triclosan-coated sutures
Number of subjects: 177

Group type: COMPARATOR
Intervention: Control group (1/0 monofilament polypropylene, 3/0 polyglactin, 3/0 polypropylene)
Number of subjects: 177

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 177
Study: 25805891

Group type: EXPERIMENTAL
Intervention: Personalized caregiver support provided by a team led by a care coordinator of the person with dementia
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned in the abstract)
Number of subjects: 61
Study: 24500147

Group type: EXPERIMENTAL
Intervention: Dietary calcium intake (1000 mg Ca)
Number of subjects: 7569

Group type: EXPERIMENTAL
Intervention: Risk alleles from a score of 6 WC-associated SNPs with dietary calcium intake (1000 mg Ca)
Number of subjects: 7569

Group type: COMPARATOR
Intervention: Dietary calcium intake
Number of subjects: 7569
Study: 22936457

Group type: EXPERIMENTAL
Intervention: Propionyl-L-carnitine (PLC)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Saline solution (Control)
Number of subjects: 48
Study: 20929598

Group type: EXPERIMENTAL
Intervention: Pranlukast (225 mg, b.i.d.)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Salmeterol (100 μg, b.i.d.)
Number of subjects: 49
Study: 18356628

Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lipid-lowering drug therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of fibrate or nicotinic acid with LDL cholesterol-lowering drug
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LDL cholesterol-lowering drug therapy
Number of subjects: 0
Study: 16038024

Group type: EXPERIMENTAL
Intervention: Oral Xeloda 1,000 mg/m2 administered twice daily from d 1 to 14
Number of subjects: 131

Group type: COMPARATOR
Intervention: Calcium folinate (CF) 200 mg/m2 as a 2-h intravenous infusion followed by 5-FU 600 mg/m2 intravenously for 4-6 h on d 1-5
Number of subjects: 131
Study: 12447029

Group type: EXPERIMENTAL
Intervention: Fluoxetine (up to 60 mg/day for 6 weeks, then up to 80 mg/day for 8 weeks)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Fluoxetine responders (n = 11)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 10337457

Group type: EXPERIMENTAL
Intervention: Subcutaneous injections of fermented and unfermented aqueous extracts of Viscum album L. (Iscador Qu Spezial and Viscum album QuFrF)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Subcutaneous injections of fermented and unfermented aqueous extracts of Viscum album L.
Number of subjects: 47
Study: 9110055

Group type: EXPERIMENTAL
Intervention: Doxazosin (1 mg daily, increased to a maximum of 16 mg daily)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 28
Study: 1943500

Group type: EXPERIMENTAL
Intervention: Evening primrose oil (6 g per day)
Number of subjects: 15
Study: 7015693

Group type: EXPERIMENTAL
Intervention: VM-26 (30 mg/m2 iv for 5 days with 7-14 day intervals)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: VM-26 (50 mg/m2 two injections a week for 4-6 weeks)
Number of subjects: 61
Study: 31145222

Group type: EXPERIMENTAL
Intervention: MD + DEP (Mediterranean Diet + Dynamic Exercise Program)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: DEP (Dynamic Exercise Program)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: MD (Mediterranean Diet)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Control
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: MD + DEP
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: DEP
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: MD
Number of subjects: 144
Study: 31348336

Group type: EXPERIMENTAL
Intervention: Restylane 2
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Dermalax DEEP
Number of subjects: 82
Study: 28807367

Group type: EXPERIMENTAL
Intervention: Platinum therapy for OCCC
Number of subjects: 9531

Group type: COMPARATOR
Intervention: Platinum therapy for SOC
Number of subjects: 9531

Group type: EXPERIMENTAL
Intervention: Consolidative therapy with weekly Paclitaxel
Number of subjects: 9531

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 9531
Study: 26189201

Group type: EXPERIMENTAL
Intervention: rTMS (1-Hz, 20 minutes, 10 sessions)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 30

Group type: COMPARATOR
Intervention: rTMS vs Sham
Number of subjects: 30
Study: 24300820

Group type: EXPERIMENTAL
Intervention: Glatimer acetate (GA) 20 mg daily for at least 12 months
Number of subjects: 534

Group type: COMPARATOR
Intervention: Interferon‐Β 44 mg three times a week
Number of subjects: 534
Study: 20422199

Group type: EXPERIMENTAL
Intervention: High-proanthocyanidin (PA) red de-alcoholised wine (DAW) (500 mL/die, PA dose = 7 mg/kg)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Low-proanthocyanidin rosé de-alcoholised wine (DAW) (500 mL/die, PA dose = 0.45 mg/kg)
Number of subjects: 21
Study: 19478258

Group type: EXPERIMENTAL
Intervention: Doxycycline, 200 mg/day for six weeks
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 17960402

Group type: EXPERIMENTAL
Intervention: Choline-stabilized orthosilicic acid (ch-OSA) 10 mg Si/day for 9 months
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo for 9 months
Number of subjects: 48
Study: 15009707

Group type: EXPERIMENTAL
Intervention: 2,4-dinitrochlorobenzene sensitization after UVR exposure
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Diphenylcyclopropenone sensitization without UVR exposure
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Correlation between Sigma DN and Sigma DP
Number of subjects: 13
Study: 11706726

Group type: EXPERIMENTAL
Intervention: High tibial osteotomy (HTO)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Unicompartmental arthroplasty (UKA)
Number of subjects: 60
Study: 9212590

Group type: EXPERIMENTAL
Intervention: Interferon-alpha 2b (one dose administration)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-dose interferon-alpha 2b treatment (6-month course)
Number of subjects: 0
Study: 8491012

Group type: EXPERIMENTAL
Intervention: Picotamide (300 mg t.i.d.)
Number of subjects: 2304

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2304
Study: 2979683

Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Cimetidine 400 mg or 800 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 18
Study: 31163319

Group type: EXPERIMENTAL
Intervention: Training condition (gaze-contingent music reward design)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Yoked control condition
Number of subjects: 85
Study: 29168087

Group type: EXPERIMENTAL
Intervention: Joint Attention Mediated Learning (JAML) intervention
Number of subjects: 144

Group type: COMPARATOR
Intervention: Community control
Number of subjects: 144
Study: 26197839

Group type: EXPERIMENTAL
Intervention: Intravenous sildenafil (single dose during cardiac catheterisation)
Number of subjects: 20
Study: 25473190

Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg per day for 2 weeks (2W group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Esomeprazole 20 mg per day for 4 weeks (4W group)
Number of subjects: 60
Study: 21870906

Group type: EXPERIMENTAL
Intervention: Red clover isoflavones (80 mg, two daily capsules)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Placebo (equal appearance)
Number of subjects: 109
Study: 20367823

Group type: EXPERIMENTAL
Intervention: Medication Alliance training (expert group)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Medication Alliance training (novice group)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Control group (baseline comparison)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Post-test scores comparison
Number of subjects: 113
Study: 18374024

Group type: EXPERIMENTAL
Intervention: Prophylactic ceftriaxone
Number of subjects: 97

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study: 15680290

Group type: EXPERIMENTAL
Intervention: eszopiclone 1mg
Number of subjects: 436

Group type: EXPERIMENTAL
Intervention: eszopiclone 2mg
Number of subjects: 436

Group type: EXPERIMENTAL
Intervention: eszopiclone 3mg
Number of subjects: 436

Group type: EXPERIMENTAL
Intervention: eszopiclone 3.5mg
Number of subjects: 436

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 436
Study: 12057880

Group type: EXPERIMENTAL
Intervention: Trained Hispanic lay advocates (Embajadoras)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Untrained Hispanic women
Number of subjects: 98

Group type: COMPARATOR
Intervention: Untrained Anglo controls
Number of subjects: 98
Study: 10471986

Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg daily for 11 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 8734139

Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg (morning dose), increased to 10 mg if clinically effective
Number of subjects: 83

Group type: COMPARATOR
Intervention: Diltiazem 180 mg (in three divided doses), increased to 240 mg if clinically effective
Number of subjects: 83
Study: 1833969

Group type: EXPERIMENTAL
Intervention: Laser probe (initially used as a nonheated mechanical device, then heated if unsuccessful)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard guidewire and balloon dilation method
Number of subjects: 20
Study: 6138935

Group type: EXPERIMENTAL
Intervention: Pindolol (nonselective, 10 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Metoprolol (beta 1‐receptor selective, 100 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Pindolol (15 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Metoprolol (200 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Acebutolol (cardioselective, 500 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Non-selective blockade (pindolol)
Number of subjects: 8
Study: 31901648

Group type: EXPERIMENTAL
Intervention: Coping Power intervention (24-session universal prevention adaptation)
Number of subjects: 839

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 839
Study: 30646532

Group type: EXPERIMENTAL
Intervention: WSP-MR (two packs a day for a total of 132 g of WSP)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Normal diet (non-WSP group)
Number of subjects: 58
Study: 29086798

Group type: EXPERIMENTAL
Intervention: Performance feedback
Number of subjects: 26

Group type: COMPARATOR
Intervention: General feedback
Number of subjects: 26
Study: 26815361

Group type: EXPERIMENTAL
Intervention: Acute stress (n=50)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (n=50)
Number of subjects: 100
Study: 24506576

Group type: EXPERIMENTAL
Intervention: Rehabilitation-aripiprazole group (RA group)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control-aripiprazole group (CA group)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control-risperidone group (CR group)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Rehabilitation-risperidone group (RR group)
Number of subjects: 43
Study: 22486209

Group type: EXPERIMENTAL
Intervention: 500 mL of water before blood donation
Number of subjects: 2464

Group type: COMPARATOR
Intervention: No water before blood donation (control)
Number of subjects: 2464

Group type: EXPERIMENTAL
Intervention: 500 mL of water
Number of subjects: 2464

Group type: COMPARATOR
Intervention: No water (control)
Number of subjects: 2464
Study: 17207124

Group type: EXPERIMENTAL
Intervention: Group B (leaflet and assessment)
Number of subjects: 975

Group type: COMPARATOR
Intervention: Group A (leaflet only)
Number of subjects: 975
Study: 16369229

Group type: EXPERIMENTAL
Intervention: EZE/SIMVA (10/20 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EZE/SIMVA (10/10, 10/20, or 10/40 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Atorvastatin (10 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Simvastatin (20 mg)
Number of subjects: 0
Study: 12773609

Group type: EXPERIMENTAL
Intervention: Group homes
Number of subjects: 114

Group type: COMPARATOR
Intervention: Independent apartments
Number of subjects: 114
Study: 10488363

Group type: EXPERIMENTAL
Intervention: Dexamethasone 24 mg intramuscularly in two divided doses 24 hours apart
Number of subjects: 204

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 204
Study: 8604599

Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 gel 2 mg intravaginally
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 gel 0.5 mg intracervically
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 gel 1 mg intravaginally
Number of subjects: 110
Study: 1757608

Group type: EXPERIMENTAL
Intervention: 0.05% halobetasol propionate ointment
Number of subjects: 127

Group type: COMPARATOR
Intervention: 0.05% clobetasol 17-propionate ointment
Number of subjects: 127
Study: 6623020

Group type: EXPERIMENTAL
Intervention: Enteric-coated tablet
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Microcrystalline tablet
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Capsule containing enterosoluble granules
Number of subjects: 9
Study: 29909057

Group type: EXPERIMENTAL
Intervention: Culturally adapted cognitive behavioral stress management (C-CBSM) intervention for 10 weeks
Number of subjects: 260

Group type: COMPARATOR
Intervention: Non-culturally adapted cognitive behavioral stress management (CBSM) intervention for 10 weeks
Number of subjects: 260
Study: 26879693

Group type: EXPERIMENTAL
Intervention: Target-controlled noradrenaline infusion to manipulate blood pressure (BP) during surgery
Number of subjects: 105
Study: 25365681

Group type: EXPERIMENTAL
Intervention: 90-day hospital-based transitional care program
Number of subjects: 512
Study: 23292523

Group type: EXPERIMENTAL
Intervention: 400 μg salbutamol
Number of subjects: 65

Group type: COMPARATOR
Intervention: Inhaled placebo
Number of subjects: 65

Group type: COMPARATOR
Intervention: Baseline measurements
Number of subjects: 65
Study: 21432607

Group type: EXPERIMENTAL
Intervention: Manualized dialectical behavioural therapy (DBT) plus methylphenidate
Number of subjects: 448

Group type: COMPARATOR
Intervention: Clinical management plus methylphenidate
Number of subjects: 448

Group type: COMPARATOR
Intervention: Manualized dialectical behavioural therapy (DBT) plus placebo
Number of subjects: 448

Group type: COMPARATOR
Intervention: Clinical management plus placebo
Number of subjects: 448
Study: 19027409

Group type: EXPERIMENTAL
Intervention: Mediterranean exchange list diet with telephone counseling
Number of subjects: 69

Group type: COMPARATOR
Intervention: Usual diet
Number of subjects: 69
Study: 17113204

Group type: EXPERIMENTAL
Intervention: High-retrieval tasks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-retrieval tasks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Eyes closed condition (Experiment 3)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No-task waiting period
Number of subjects: 0
Study: 12701995

Group type: EXPERIMENTAL
Intervention: Caffeine reduction by 90% or greater for 30 days
Number of subjects: 88

Group type: COMPARATOR
Intervention: Usual caffeine consumption
Number of subjects: 88
Study: 10998026

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate aqueous nasal spray (FPANS)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 8864022

Group type: EXPERIMENTAL
Intervention: Heparin-coated CPB circuits (Group HC)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Noncoated CPB circuits (Group C)
Number of subjects: 16
Study: 1497522

Group type: EXPERIMENTAL
Intervention: Cryotherapy in one eye for patients with bilateral threshold retinopathy of prematurity
Number of subjects: 4099

Group type: COMPARATOR
Intervention: No therapeutic ocular procedures (control group)
Number of subjects: 4099
Study: 6603567

Group type: EXPERIMENTAL
Intervention: Surgical stapling transection of the oesophagus
Number of subjects: 20

Group type: COMPARATOR
Intervention: Percutaneous transhepatic obliteration
Number of subjects: 20
Study: 31111436

Group type: EXPERIMENTAL
Intervention: NOF thresholds
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: NOGG thresholds
Number of subjects: 264
Study: 29659685

Group type: EXPERIMENTAL
Intervention: Curcumin supplementation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Curcumin combined with long-chain omega-3 fatty acids
Number of subjects: 0
Study: 26365144

Group type: EXPERIMENTAL
Intervention: Extracorporeal shockwave treatment (ESWT)
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided percutaneous lavage (UGPL)
Number of subjects: 201
Study: 25835231

Group type: EXPERIMENTAL
Intervention: Vitamin C deficiency (biochemical depletion below 11 µmol/L)
Number of subjects: 322

Group type: COMPARATOR
Intervention: Normal vitamin C levels
Number of subjects: 322
Study: 22284636

Group type: EXPERIMENTAL
Intervention: Bard PowerPICC Solo2
Number of subjects: 53

Group type: COMPARATOR
Intervention: Cook Turbo-Ject
Number of subjects: 53
Study: 19652568

Group type: EXPERIMENTAL
Intervention: Segmental posterior instrumentation with 2 levels above and 2 levels below the fracture level fixation
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Segmental posterior instrumentation with fracture level screw incorporation
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Short-segment posterior instrumentation with 1 level above and 1 level below
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Short-segment posterior instrumentation with fracture level screw incorporation
Number of subjects: 72
Study: 17521930

Group type: EXPERIMENTAL
Intervention: Asasantin (Dipyridamole 200mg/Aspirin 25mg) twice daily (group I; n=39)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Asasantin plus 75 mg Clopidogrel once daily (group II; n=33)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Asasantin plus Rheomacrodex (Dextran 40) 100g/L iv; 500 ml (group III; n=30)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Asasantin (group I)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Clopidogrel (group II)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Rheomacrodex (group III)
Number of subjects: 102

Group type: COMPARATOR
Intervention: All APT groups
Number of subjects: 102
Study: 15567642

Group type: EXPERIMENTAL
Intervention: Propofol-spinal anesthesia
Number of subjects: 150

Group type: COMPARATOR
Intervention: Propofol-fentanyl anesthesia
Number of subjects: 150
Study: 11443224

Group type: EXPERIMENTAL
Intervention: Pioglitazone (30 mg daily for 6 months)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 106
Study: 9531962

Group type: EXPERIMENTAL
Intervention: Allergen inhalation (very low doses)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 7974930

Group type: EXPERIMENTAL
Intervention: Diltiazem (calcium channel blocker)
Number of subjects: 40
Study: 2524959

Group type: COMPARATOR
Intervention: Placebo for both dipyridamole and aspirin
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Dipyridamole (75 mg) and aspirin (324 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Dipyridamole (75 mg) and placebo for aspirin
Number of subjects: 12
Study: 4413307

Group type: EXPERIMENTAL
Intervention: Nissen procedure
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Belsey procedure
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Hill procedure
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: All procedures
Number of subjects: 45

Group type: COMPARATOR
Intervention: Nissen and Belsey
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Nissen and Hill repairs
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Belsey repair
Number of subjects: 45
Study: 31923231

Group type: COMPARATOR
Intervention: People in prison
Number of subjects: 1530

Group type: COMPARATOR
Intervention: People recently released from prison
Number of subjects: 1530
Study: 30991614

Group type: EXPERIMENTAL
Intervention: Early high-dose erythropoietin (EPO)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28249572

Group type: EXPERIMENTAL
Intervention: Ertapenem (de-escalation therapy)
Number of subjects: 66
Study: 25567131

Group type: EXPERIMENTAL
Intervention: Total arterial grafting (TAG)
Number of subjects: 60

Group type: COMPARATOR
Intervention: LIMA-LAD plus saphenous vein grafts (LIMA+SVG)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups (TAG and LIMA+SVG)
Number of subjects: 60
Study: 23979082

Group type: EXPERIMENTAL
Intervention: Plastic bag intervention
Number of subjects: 271
Study: 20978643

Group type: EXPERIMENTAL
Intervention: SolidBond/Durafill (D/SB)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Syntac classic/Heliomolar (H/SC)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Scotchbond1/ Experiment127 (EXI/SB1)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Optibond FL/Point 4 (P4/OBFL)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Prime&Bond NT/Esthet‐X (EX/PBNT)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: ART Bond/ Miris (MIR/ART)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: SE Bond/Clearfil ST (CLE/SE‐B)
Number of subjects: 42